Brief: Bharat Parenterals Says U.S. FDA Conducts Surprise Inspection At Innoxel Lifesciences Vadodara Facility
21/04/2026 09:28
April 21 (Reuters) - Bharat Parenterals Ltd BATP.BO: BHARAT PARENTERALS LTD - U.S. FDA CONDUCTS SURPRISE INSPECTION AT INNOXEL LIFESCIENCES VADODARA FACILITY BHARAT PARENTERALS LTD - U.S. FDA ISSUES FIVE OBSERVATIONS UNDER VAI CLASSIFICATION Source text: ID:nBSEMcQmp Further company coverage: BATP.BO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bharat Parenterals
See all newsBrief: Bharat Parenterals Says U.S. FDA Conducts Surprise Inspection At Innoxel Lifesciences Vadodara Facility
India's Bharat Parenteral rebounds on successful completion of EU GMP inspection
Brief: Bharat Parenterals Says Innoxel Lifesciences Completes EU GMP Inspection By Belgium's FAMHP
India's Bharat Parenterals jump after unit clears US FDA inspection
Brief: Bharat Parenterals Secures $27 Mln Order For Pharmaceutical Products